Drug Repositioning: One Molecule, Multiple Indications, and the IP Architecture That Locks In the Profits

A deep-dive reference for pharma IP teams, R&D leads, and institutional investors on the science, strategy, and commercial mechanics of […]

Drug Repositioning: One Molecule, Multiple Indications, and the IP Architecture That Locks In the Profits Read Post »